RO7502175 + atezolizumab

RO7502175 + atezolizumab is an experimental combination therapy for locally advanced or metastatic solid tumors. **RO7502175** is a novel monoclonal antibody targeting **CCR8**, a chemokine receptor preferentially expressed on regulatory T cells (Treg); it is designed to deplete intra-tumoral CCR8+ Treg cells via antibody-dependent cell-mediated cytotoxicity (ADCC), aiming to relieve immunosuppression in the tumor microenvironment and promote anti-tumor T-cell activity. **Atezolizumab** is a humanized IgG1 monoclonal antibody targeting **PD-L1**, approved for several cancers, that blocks PD-L1 interaction with PD-1 and B7-1 (CD80) on T cells, thereby reinvigorating T-cell mediated anti-tumor activity. The combination aims to enhance anti-tumor immune response by simultaneously depleting suppressive Treg cells (via RO7502175) and restoring T-cell function (via atezolizumab)[1][2][3].

Other names

RO7502175 + Tecentriq